1.Broderick, J, Brott, T, Kothari, R, et al.The greater Cincinnati/Northern Kentucky Stroke Study. Stroke. 1998;29:415–421.
2.Garraway, WM, Whisnant, JP. The changing pattern of hypertension and the declining incidence of stroke. JAMA. 1987;258:214–217.
3.Wolf, PA, D'Agostino, RB, O'Neal, MA, et al.Secular trends in stroke incidence and mortality: the Framingham Study. Stroke. 1992;23:1551–1555.
4.Brown, RD, Whisnant, JP, Sicks, RD, et al.Stroke incidence, prevalence and survival: secular trends in Rochester, Minnesota through 1989. Stroke. 1996;27:373–380.
5.Gillum, RF. Stroke in blacks. Stroke. 1988;19:1–9.
6.Howard, G, Anderson, R, Sorlie, P, et al.Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks: the National Longitudinal Mortality Study. Stroke. 1994;25:2120–2125.
7.Giles, WH, Kittner, SJ, Hebel, JR, et al.Determinants of black-white differences in the risk of cerebral infarction. Arch Intern Med. 1995;155:1319–1324.
8.Sacco, RL, Boden-Albala, B, Gan, R, et al.Stroke incidence among white, black and Hispanic residents of an urban community. Am J Epidemiol. 1998;147:259–268.
9.Rosenwaike, I. Mortality among the Puerto Rican born in New York City. Social Science Quarterly. 1983;64:375–385.
10.Joutel, A, Corpechot, C, Ducros, A, et al.Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–710.
11.Kannel, WB, Wolf, PA, Verter, J, McNamara, PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham Study. JAMA. 1970;214:301–310.
12.Menotti, A, Jacobs, DR Jr, Blackburn, H, et al.Twenty-five-year prediction of stroke deaths in the Seven Countries Study: the role of blood pressure and its changes. Stroke. 1996;27:381–387.
13.Collins, R, MacMahon, S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272–298.
14.Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:633–638.
15.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–3264.
16.Fagard, RH, Staessen, JA. Treatment of isolated systolic hypertension in the elderly. The Syst-Eur trial. Clin Exp Hypertens. 1999;21:491–497.
17.Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke in the Framingham Study. Stroke. 1991;22:983–988.
18.Brand, FN, Abbott, RD, Kannel, WB, Wolf, PA. Characteristics and prognosis of lone atrial fibrillation. JAMA. 1985;254:3449–3453.
19.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized trials. Arch Intern Med. 1994;154:1449–1457.
20.Kannel, WB, Wolf, PA, Verter, J. Manifestations of coronary artery disease predisposing to stroke. The Framingham Study. JAMA. 1983;250:2942–2946.
21.Loh, E, Sutton, MS, Wun, CC, et al.Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251–257.
22.Roberts, JK, Omarali, I, Ditullio, MR, et al.Valvular strands and cerebral ischemia. Effects of demographics and strand characteristics. Stroke. 1997;28:2185–2188.
23.Gilon, D, Buonanno, FS, Joffe, M, et al.Lack of evidence of an association between mitralvalve prolapse and stroke in young patients. N Engl J Med. 1999;341:8–13.
24.Hausmann, D, Mugge, A, Daniel, WC. Identification of patent foramen ovale permitting paradoxical embolism. J Am Coll Cardiol. 1995;26:1030–1038.
25.DiTullio, MR, Sacco, RL, Gopal, A, et al.Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461–465.
26.Amarenco, P, Duyckaerts, C, Tzourio, C. The prevalance of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med. 1992;326:222–225.
27.Amarenco, P, Cohen, A, Tzourio, C. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med. 1994;331:1474–1479.
28.Horowitz, DR, Tuhrim, S, Budd, J, Goldman, ME. Aortic plaque in a series of patients with brain ischemia: diagnosis by transesophageal echocardiography. Neurology. 1992;42:1602–1604.
29.Horowitz, DR, Tuhrim, S, Weinberger, JM, Budd, J, Alweiss, CS, Goldman, ME. Transesophageal echocardiography: diagnostic and clinical applications in the evaluation of the stroke patient. Journal of Stroke and Cerebrovascular Diseases. 1997;6:332–336.
30.Iso, H, Jacobs, DRJ, Wentworth, D, et al.Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the MRFIT. N Engl J Med. 1989;320:9804–9810.
31.Prospective Studies Collaboration. Cholesterol diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647–1653.
32.Fried, LP, Borhani, NO, Enright, P, et al.The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–276.
33.Hebert, PR, Gaziano, JM, Chan, KS, Hennekens, CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA. 1997;278:313–321.
34.The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with mavastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:349–357.
35.Furberg, CD. Natural statins and stroke risk. Circulation. 1999;99:185–188.
36.Rubins, HB, Robins, SJ, Collins, D, et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418.
37.Wolf, PA, D'Agostino, RB, Kannel, WB, et al.Cigarette smoking as a risk factor for stroke. JAMA. 1998;259:1025–1029.
38.Kawacki, I, Colditz, GA, Stampfer, MJ, et al.Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269:232–236.
39.Lindegaard, B, Hillbom M. Associations between brain infarction, diabetes and alcoholism: observations from the Gothenburg population cohort study. Acta Neurol Scand. 1987;75:195–200.
40.Abbott, RD, Donahue, RP, MacMahon, SW, et al.Diabetes and the risk of stroke: the Honolulu Heart Program. JAMA. 1987;257:949–956.
41.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–712.
42.Camargo, C. Moderate alcohol consumption and stroke. Stroke. 1989;20:1611–1626.
43.Sacco, RL, Elkind, M, Boden-Albala, B, et al.The protective effect of moderate alcohol consumption on ischemic stroke. JAMA. 1999;281:1112–1120.
44.The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069–2073.
45.Muir, KW, Squire, IB, Alivan, W, Lees, KR. Anticardiolipin antibodies in an unselected stroke population. Lancet. 1994;344:452–456.
46.Ginsburg, KS, Liang, MH, Newcomer, L, et al.Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997–1002.
47.Tuhrim, S, Rand, JH, Wu, X, et al.Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561–1565.
48.Tuhrim, S. Rand, JH, Wu, X, et al.Antiphosphatidylserine antibodies are independently associated with ischemic stroke. Neurology. 1999;53:1523–1527.
49.Toschi, V, Motta, A, Castelli, C, Paracchini, ML, Zerbi, D, Gibelli, A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke. 1998;29:1759–1764.
50.Rand, JH. Antiphospholipid antibody syndrome: new insights on thrombogenetic mechanisms. Am J Med Sci. 1998;316:142–151.
51.The WARSS, APASS, PICSS HAS, and GENESIS Study Groups. The feasibility of collaborative double-blind study using an anticoagulant. Cerebrovasc Dis. 1997;7:100–122.
52.Giles, WH, Croft, JB, Greenlund, KJ, Ford, LS, Kittner, SJ. Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke. 1998;29:2473–2477.
53.Perry, IJ, Refsum, H, Morris, RW, Ebrahim, SB, Ueland, PM, Shaper, AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398.
54.Chimowitz, MI, Weiss, DG, Cohen, SL, et al.Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Stroke. 1994;25:759–765.
55.Roederer, GO, Langlois, YE, Jager, KA, et al.The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke. 1984;15:605–613.
56.Wilson, PWF, Hoeg, JM, D'Agostino, RB, et al.Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337:516–522.
57.Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421–1428.
58.European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-19%) carotid stenosis. Lancet. 1991;337:1235–1243.
59.North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–451.
60.Chassin, MR. Appropriate use of carotid endarterectomy. N Engl J Med. 1998;339:1468–1471.
61.Barnett, HJM, Meldrum, HE, Eliasziw, M. The dilemma of surgical treatment for patients with asymptomatic disease. Ann Intern Med. 1995;123:723–725.
62.Wolf, PA, D'Agostino, RB, Belanger, AJ, Kannel, WB. Probability of stroke: a risk profile from The Framingham Study. Stroke. 1991;22:312–318.
63.Gorelick, PB. Stroke prevention: an opportunity for efficient utilization of health resources during the coming decade. Stroke. 1994;25:220–224.